HMGB2 and pancreatic neoplasm: The expression levels of HMGB2 (high mobility group protein B2) that promotes pro-inflammatory conditions [69], which is associated with poor prognosis of pancreatic cancer and which promotes cell proliferation and survival [70], were unchanged or decreased 7-fold following short-term and long-term treatment with si-hVDAC1, respectively.